Resmed Hits Our Profit Target

RMD.ASX traded at our $9.00 profit target today. The stock has put on 20% since our buy trigger. Patience has paid off here and waiting for  todays earnings result has proven to be the right approach.

ResMed’s annual profit for the year to June 30 was $US352m on annual revenue of $US1.8b, up from $US1.7b. Revenue for the fourth quarter lifted 15 per cent to $US519m boosted by the acquisition in healthcare software group Brightree. Quarterly dividend raised to 33 US cents per share.

You're not a member!  Trial today!

Our algorithm engines will continue to track RMD.ASX for future buying opportunities and I’ll be sure to keep you informed.

RMD

Enjoy the proceeds of this quick profit!

Investor Signals Pty Ltd ABN 44 143 555 453 is a Corporate Authorised Representative CAR No. 439411 of Advisor Plus Pty Ltd AFSL 474520
© 2020 Investor Signals